Takhzyro With Long-term Use Safely Prevent HAE Attacks, Study Finds

Takhzyro With Long-term Use Safely Prevent HAE Attacks, Study Finds

302635

Takhzyro With Long-term Use Safely Prevent HAE Attacks, Study Finds

Takhzyro (lanadelumab) safely and markedly reduced the frequency of swelling attacks in people with hereditary angioedema (HAE) over 2.5 years, according to results of the HELP open-label extension (OLE) study. “This study supports the use of Takhzyro as a long-term preventative treatment option for those 12 years of age and older living with HAE who are seeking a preventative treatment option that is proven to reduce HAE attacks,” Neil Inhaber, MD, vice president, global medical…

You must be logged in to read/download the full post.